Insights and considerations in the use of biologics for managing eosinophilic exacerbations in asthma and chronic obstructive pulmonary disease
- PMID: 40400961
- PMCID: PMC12090099
- DOI: 10.21037/jtd-2024-2206
Insights and considerations in the use of biologics for managing eosinophilic exacerbations in asthma and chronic obstructive pulmonary disease
Keywords: Asthma; biologics; eosinophil; exacerbation.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2024-2206/coif). The authors have no conflicts of interest to declare.
Comment on
-
Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial.Lancet Respir Med. 2025 Jan;13(1):59-68. doi: 10.1016/S2213-2600(24)00299-6. Epub 2024 Nov 29. Lancet Respir Med. 2025. PMID: 39615502 Clinical Trial.
References
Publication types
LinkOut - more resources
Full Text Sources